Company news
Mind Cure Health Inc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Mind Cure Health Inc. (to be renamed LNG energy group corp.) announces completion of business combination transaction
August 15, 2023
Mind Cure announces closing of LNG energy's subscription receipt financing
August 5, 2023
Mind Cure announces LNG energy Group credit agreement in the amount of U.S. $70 million to acquire lewis energy colombia, inc.
July 27, 2023
Mind Cure Health Inc. announces closing of the first tranche of LNG energy group's subscription receipt financing
June 9, 2023
Mind Cure and LNG energy group provide update on previously announced business combination transaction
June 8, 2023
Mind Cure closes previously announced private placement
May 11, 2023
CSE Bulletin: Halted for Fundamental Change - Mind Cure Health Inc. (MCUR, MCUR.WT)
May 9, 2023
Mind Cure and LNG energy group enter into arrangement agreement with respect to previously announced business combination transaction
May 5, 2023
MINDCURE Announces Financial Results for the Third Quarter of Fiscal 2023
April 20, 2023
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2023
January 25, 2023
Mind Cure enters into binding letter of intent with LNG energy group
November 18, 2022
Mind Cure enters into binding letter of intent with LNG energy group
November 18, 2022
MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023
October 26, 2022
MINDCURE Announces Financial Results for Fiscal 2022
September 13, 2022
MINDCURE Announces Financial Results for the Third Quarter of Fiscal 2022
April 26, 2022
MINDCURE Provides Update on Strategic Review
March 16, 2022
MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program
March 2, 2022
MINDCURE Announces Strategic Review
February 10, 2022
MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform
February 3, 2022
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022
January 25, 2022
MINDCURE to Participate in the H.C. Wainwright Bioconnect Conference in January 2022
January 6, 2022
MINDCURE Announces Certification of HIPAA Compliance, Bringing iSTRYM Closer to Commercial Deployment in the Second Quarter of 2022
December 16, 2021
MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer
December 14, 2021
MINDCURE to Participate in Upcoming Conferences in December 2021
December 2, 2021
MINDCURE Provides Update on Studies and Clinical Trials
November 4, 2021
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE's Digital Therapeutics Platform
October 28, 2021
MINDCURE Announces Participation at Upcoming Events in November 2021
October 27, 2021
MINDCURE Announces Financial Results for the First Quarter of Fiscal 2022
October 26, 2021
MINDCURE to Webcast Live at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021
October 7, 2021
MINDCURE Announces Commencement of Trading on the OTCQX Best Market
September 30, 2021
MINDCURE Announces Financial Results for Fiscal 2021
August 31, 2021
MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team
August 10, 2021
MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor
August 4, 2021
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
July 27, 2021
MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound
July 13, 2021
MINDCURE Adopts Advance Notice Policy
July 12, 2021
Maxim Group Initiates Coverage of Mind Cure Health
June 30, 2021
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
June 17, 2021
MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
June 3, 2021
Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
May 20, 2021
MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children's Hospital, as Company Advisor
May 19, 2021
MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM's Market Launch, Delivering Mental Wealth
April 29, 2021
MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM
April 27, 2021
MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors
April 22, 2021
MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions
April 21, 2021
MINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment
April 14, 2021
MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company's Psychedelic Digital Therapeutics Technology Platform
April 13, 2021
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
April 8, 2021
MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients
March 31, 2021
March Psychedelic Capital Investigates Ethical IP and Financial Instruments
March 30, 2021